Given the remarkable clinical success of the Bcl-2 specific inhibitor, venetoclax or venclaxta, in treating relapsed or refractory chronic lymphocytic leukemia (CLL), many have sought to develop a Mcl-1 specific inhibitor. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.